1. Home
  2. XCUR vs BMEA Comparison

XCUR vs BMEA Comparison

Compare XCUR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XCUR
  • BMEA
  • Stock Information
  • Founded
  • XCUR 2011
  • BMEA 2017
  • Country
  • XCUR United States
  • BMEA United States
  • Employees
  • XCUR N/A
  • BMEA N/A
  • Industry
  • XCUR Biotechnology: Pharmaceutical Preparations
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • XCUR Health Care
  • BMEA Health Care
  • Exchange
  • XCUR Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • XCUR 59.0M
  • BMEA 65.8M
  • IPO Year
  • XCUR N/A
  • BMEA 2021
  • Fundamental
  • Price
  • XCUR $7.45
  • BMEA $1.95
  • Analyst Decision
  • XCUR
  • BMEA Strong Buy
  • Analyst Count
  • XCUR 0
  • BMEA 10
  • Target Price
  • XCUR N/A
  • BMEA $22.30
  • AVG Volume (30 Days)
  • XCUR 252.6K
  • BMEA 2.3M
  • Earning Date
  • XCUR 08-12-2025
  • BMEA 07-30-2025
  • Dividend Yield
  • XCUR N/A
  • BMEA N/A
  • EPS Growth
  • XCUR N/A
  • BMEA N/A
  • EPS
  • XCUR N/A
  • BMEA N/A
  • Revenue
  • XCUR N/A
  • BMEA N/A
  • Revenue This Year
  • XCUR N/A
  • BMEA N/A
  • Revenue Next Year
  • XCUR N/A
  • BMEA N/A
  • P/E Ratio
  • XCUR N/A
  • BMEA N/A
  • Revenue Growth
  • XCUR N/A
  • BMEA N/A
  • 52 Week Low
  • XCUR $1.44
  • BMEA $1.29
  • 52 Week High
  • XCUR $36.00
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • XCUR 45.76
  • BMEA 50.29
  • Support Level
  • XCUR $5.05
  • BMEA $1.58
  • Resistance Level
  • XCUR $7.36
  • BMEA $3.08
  • Average True Range (ATR)
  • XCUR 1.04
  • BMEA 0.17
  • MACD
  • XCUR 0.15
  • BMEA -0.03
  • Stochastic Oscillator
  • XCUR 65.31
  • BMEA 56.92

About XCUR Exicure Inc.

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: